Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA‘s (NASDAQ:SNY) Phase 3 LIBERTY-CUPID Study C of Dupixent (dupilumab) was successful.
The study met the primary and key secondary endpoints for uncontrolled, biologic-naïve chronic spontaneous urticaria (CSU) receiving background therapy with antihistamines.
CSU is a chronic skin condition that causes hives and persistent itch. The positive trial confirms results from Study A, the first Phase 3 trial of Dupixent in this setting.
Also Read: Regeneron Pharmaceuticals’ Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs.
Earlier this year, Japan was the first country in the world to approve and launch Dupixent for adult and adolescent CSU patients based on the results from Study A.
At 24 weeks, efficacy among patients receiving Dupixent compared to placebo was as follows:
8.64-point reduction in itch severity from baseline with Dupixent versus a 6.10-point reduction ...
